Franciosa J A, Cohn J N
Circulation. 1979 Jun;59(6):1085-91. doi: 10.1161/01.cir.59.6.1085.
Resting hemodynamics improve during vasodilator administration in patients, with congestive heart failure (CHF), but the effects of these agents on exercise is unknown. Twenty-two patients with class II or III CHF performed bicycle exercise to symptomatic maximum before and 90 minutes after random double-blind administration of oral hydralazine (100 mg) and isosorbide dinitrate (40 mg) (11 patients, group 1) or placebo (11 patients, group 2). Exercise duration was unchanged after treatment in either group. Maximal oxygen consumption changed insignificantly in both groups, from 12.6 +/- 1.2 (SEM) to 13.6 +/- 1.6 ml/kg/min in group 1, and from 11.7 +/- 1.4 to 13.4 +/- 1.7 ml/kg/min in group 2. Maximal cardiac index was unchanged in both group 1 (4.00 +/- 0.33 to 4.41 +/- 0.29 l/min/m2) and group 2 (4.11 +/- 0.43 to 4.14 +/- 0.42 l/min/m2). Systemic vascular resistance at peak exercise was also unchanged in both group 1 (14.1 +/- 1.6 to 11.8 +/- 1.0 units) and group 2 (14.7 +/- 1.6 to 13.5 +/- 1.6 units). at submaximal exercise (300 kilopond-meters/min), however, cardiac index after treatment increased in group 1 (0.51 +/- 0.18 l/min/m2, p less than 0.05) and systemic vascular resistance decreased (-3.3 +/- 1.3 units, p less than 0.05), but were unchanged in group 2. Thus, although vasodilators do not improve maximal exercise capacity acutely, they can improve hemodynamics at lower work loads which may, therefore, be better tolerated in patients with CHF.
在充血性心力衰竭(CHF)患者中,使用血管扩张剂时静息血流动力学状况会有所改善,但这些药物对运动的影响尚不清楚。22例II级或III级CHF患者在随机双盲口服肼屈嗪(100mg)和硝酸异山梨酯(40mg)(11例患者,第1组)或安慰剂(11例患者,第2组)之前及之后90分钟进行自行车运动,直至出现症状性最大值。两组治疗后运动持续时间均未改变。两组的最大耗氧量变化均不显著,第1组从12.6±1.2(标准误)ml/kg/min增至13.6±1.6 ml/kg/min,第2组从11.7±1.4增至13.4±1.7 ml/kg/min。第1组(4.00±0.33至4.41±0.29 l/min/m²)和第2组(4.11±0.43至4.14±0.42 l/min/m²)的最大心脏指数均未改变。两组在运动峰值时的全身血管阻力也未改变,第1组(14.1±1.6至11.8±1.0单位)和第2组(14.7±1.6至13.5±1.6单位)。然而,在次最大运动(300千克米/分钟)时,第1组治疗后的心脏指数增加(0.51±0.18 l/min/m²,p<0.05),全身血管阻力降低(-3.3±1.3单位,p<0.05),而第2组则未改变。因此,尽管血管扩张剂不能急性改善最大运动能力,但它们可以在较低工作负荷下改善血流动力学,因此CHF患者可能对其耐受性更好。